HBM Holdings Ltd. Announces Global Phase 2 POLARIS Trial for Long-Acting Anti-TSLP Antibody in Asthma

Reuters

07-23

HBM Holdings Ltd. Announces Global Phase 2 POLARIS Trial for Long-Acting Anti-TSLP Antibody in Asthma

Harbour BioMed has announced the initiation of the POLARIS clinical study, a global, randomized, double-blind, placebo-controlled Phase 2 trial evaluating the dosing, safety, and efficacy of HBM9378/WIN378 in patients with asthma. This trial, conducted in partnership with Windward Bio AG, aims to assess the potential of HBM9378/WIN378 as a long-acting, fully human anti-TSLP antibody with twice-yearly dosing. Initial data from the study are expected to be available in mid-2026. Additionally, HBM9378/WIN378 is being prepared for clinical trials in COPD, with a global program set to commence in mid-2026. The development of HBM9378/WIN378 underscores its potential to address significant unmet needs in treating advanced respiratory diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN33802) on July 23, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2553724867"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553724867\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2553724867?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-23 20:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553724867","market":"fut","top_or_hot":-1,"title":"HBM Holdings Ltd. Announces Global Phase 2 POLARIS Trial for Long-Acting Anti-TSLP Antibody in Asthma","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      HBM Holdings Ltd. Announces Global Phase 2 POLARIS Trial for Long-Acting Anti-TSLP Antibody in Asthma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Harbour BioMed has announced the initiation of the POLARIS clinical study, a global, randomized, double-blind, placebo-controlled Phase 2 trial evaluating the dosing, safety, and efficacy of HBM9378/WIN378 in patients with asthma. This trial, conducted in partnership with Windward Bio AG, aims to assess the potential of HBM9378/WIN378 as a long-acting, fully human anti-TSLP antibody with twice-yearly dosing. Initial data from the study are expected to be available in mid-2026. Additionally, HBM9378/WIN378 is being prepared for clinical trials in COPD, with a global program set to commence in mid-2026. The development of HBM9378/WIN378 underscores its potential to address significant unmet needs in treating advanced respiratory diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN33802) on July 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HBM Holdings Ltd. Announces Global Phase 2 POLARIS Trial for Long-Acting Anti-TSLP Antibody in Asthma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHBM Holdings Ltd. Announces Global Phase 2 POLARIS Trial for Long-Acting Anti-TSLP Antibody in Asthma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-23 20:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      HBM Holdings Ltd. Announces Global Phase 2 POLARIS Trial for Long-Acting Anti-TSLP Antibody in Asthma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Harbour BioMed has announced the initiation of the POLARIS clinical study, a global, randomized, double-blind, placebo-controlled Phase 2 trial evaluating the dosing, safety, and efficacy of HBM9378/WIN378 in patients with asthma. This trial, conducted in partnership with Windward Bio AG, aims to assess the potential of HBM9378/WIN378 as a long-acting, fully human anti-TSLP antibody with twice-yearly dosing. Initial data from the study are expected to be available in mid-2026. Additionally, HBM9378/WIN378 is being prepared for clinical trials in COPD, with a global program set to commence in mid-2026. The development of HBM9378/WIN378 underscores its potential to address significant unmet needs in treating advanced respiratory diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN33802) on July 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250723:nNDL7Kc24N:1","article_id":"2553724867","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553724867","pubTimestamp":1753274241,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Harbour BioMed has announced the initiation of the POLARIS clinical study, a global, randomized, double-blind, placebo-controlled Phase 2 trial evaluating the dosing, safety, and efficacy of HBM9378/WIN378 in patients with asthma. This trial, conducted in partnership with Windward Bio AG, aims to assess the potential of HBM9378/WIN378 as a long-acting, fully human anti-TSLP antibody with twice-yearly dosing. Initial data from the study are expected to be available in mid-2026. Additionally, HBM9378/WIN378 is being prepared for clinical trials in COPD, with a global program set to commence in mid-2026. The development of HBM9378/WIN378 underscores its potential to address significant unmet needs in treating advanced respiratory diseases.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interp","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","BK1161":"生物科技","BK1583":"高瓴概念","02142":"和铂医药-B"},"translate_title":"HBM Holdings Ltd.宣布长效抗TSLP抗体治疗哮喘的全球2期POLARIS试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02142":0.9},"content_text":"HBM Holdings Ltd. Announces Global Phase 2 POLARIS Trial for Long-Acting Anti-TSLP Antibody in Asthma\n    \n\n        Harbour BioMed has announced the initiation of the POLARIS clinical study, a global, randomized, double-blind, placebo-controlled Phase 2 trial evaluating the dosing, safety, and efficacy of HBM9378/WIN378 in patients with asthma. This trial, conducted in partnership with Windward Bio AG, aims to assess the potential of HBM9378/WIN378 as a long-acting, fully human anti-TSLP antibody with twice-yearly dosing. Initial data from the study are expected to be available in mid-2026. Additionally, HBM9378/WIN378 is being prepared for clinical trials in COPD, with a global program set to commence in mid-2026. The development of HBM9378/WIN378 underscores its potential to address significant unmet needs in treating advanced respiratory diseases.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN33802) on July 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}